Top

Published in:

01-07-2013 | Brief Research Article

Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients

Authors: F. Pietrantonio, P. Biondani, M. Milione, F. Melotti, G. Bertarelli, F. Perrone, F. de Braud, L. Mariani, G. Fanetti, D. Cortinovis, M. Di Bartolomeo

Published in: Clinical and Translational Oncology | Issue 7/2013

Abstract

Background

Currently, first-line chemotherapy in advanced colorectal cancer is not tailored on predictive biomarkers. Bax proapoptotic protein may correlate to chemosensitivity and differential response to irinotecan or oxaliplatin-based combinations.

Methods

Bax expression was assessed by immunohistochemistry in 49 advanced colorectal cancer patients enrolled at our institution from 2002 to 2004 within a multicenter, phase II, randomized trial of first-line UFT/leucovorin/irinotecan (TEGAFIRI) versus UFT/leucovorin/oxaliplatin (TEGAFOX).

Results

Bax-positive and negative samples were 49 and 51 %. Response was significantly lower in Bax positive (25 %) as compared to Bax negative (56 %) (Odds ratio = 0.26; p = 0.03). No significant difference was noted in TEGAFOX subgroup; in TEGAFIRI arm, responses were lower in Bax positive (18 %) than Bax negative (67 %) (Odds ratio = 0.11; p = 0.03). No difference in terms of progression-free and overall survival was observed according to Bax.

Conclusion

Bax-negative colorectal cancer may identify a specific phenotype of patients with significantly higher chance to respond to doublet irinotecan-based chemotherapy.

Jemal A, Siegel R, Ward E et al (2009) Cancer statistics. CA Cancer J Clin 59:225–249PubMedCrossRef

Dienstmann R, Markman B, Tabernero J (2012) Application of monoclonal antibodies as cancer therapy in solid tumors. Curr Clin Pharmacol 7:137–145PubMedCrossRef

De Roock W, Claes B, Bernasconi D et al (2010) Effect of KRAS, BRAF, NRAS, and PI3KCA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11:753–762PubMedCrossRef

Perrone F, Lampis A, Orsenigo M et al (2009) PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 20:84–90PubMedCrossRef

Miyashita T, Reed JC (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293–299PubMedCrossRef

Jeong SH, Han JH, Kim JH et al (2011) Bax predicts outcome in gastric cancer patients treated with 5-fluorouracil, leucovorin, and oxaliplatin palliative chemotherapy. Dig Dis Sci 56:131–138PubMedCrossRef

Krajewski S, Blomqvist C, Franssila K et al (1995) Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 55:4471–4478PubMed

Kupryjanczyk J, Szymanska T, Madry R et al (2003) Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen. Br J Cancer 88:848–854PubMedCrossRef

Bajetta E, Di Bartolomeo M, Buzzoni R et al (2007) Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of a randomised phase II study. Br J Cancer 96:439–444PubMedCrossRef

10.

Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRef

11.

Pietrantonio F, Biondani P, de Braud F et al (2012) Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen. Transl Oncol 5:155–159PubMed

12.

Siena S, Sartore-Bianchi A, Di Nicolantonio F et al (2009) Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 101:1308–1324PubMedCrossRef

13.

Sinicrope FA, Sargent DJ (2012) Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. Clin Cancer Res 18:1506–1512PubMedCrossRef

14.

McDonald AC, Brown R (1998) Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors. Br J Cancer 78:745–751PubMedCrossRef

15.

Nehls O, Okech T, Hsieh CJ et al (2007) Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX. Br J Cancer 96:1409–1418PubMed

16.

Katkoori VR, Suarez-Cuervo C, Shanmugam C et al (2010) Bax expression is a candidate prognostic and predictive marker of colorectal cancer. J Gastrointest Oncol 1:76–89PubMed

17.

Paradiso A, Simone G, Lena MD et al (2001) Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer. Br J Cancer 84:651–658PubMedCrossRef

18.

Yee KS, Wilkinson S, James J et al (2009) PUMA- and Bax-induced autophagy contributes to apoptosis. Cell Death Differ 16:1135–1145PubMedCrossRef

19.

Fallik D, Borrini F, Boige V et al (2003) Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res 63:5738–5744PubMed

20.

Bras-Goncalves RA, Rosty C, Laurent-Puig P et al (2000) Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status. Br J Cancer 82:913–923PubMedCrossRef

Title: Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients
Authors: F. Pietrantonio
P. Biondani
M. Milione
F. Melotti
G. Bertarelli
F. Perrone
F. de Braud
L. Mariani
G. Fanetti
D. Cortinovis
M. Di Bartolomeo
Publication date: 01-07-2013
Publisher: Springer Milan
Published in: Clinical and Translational Oncology / Issue 7/2013
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-012-0971-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2013

GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012

Altered expression of piRNAs and their relation with clinicopathologic features of breast cancer

Association of BRCA1 promoter methylation with rs11655505 (c.2265C>T) variants and decreased gene expression in sporadic breast cancer

Management and outcome of ovarian malignancy complicating pregnancy: an analysis of 41 cases and review of the literature

Lung adenocarcinoma in the era of targeted therapies: histological classification, sample prioritization, and predictive biomarkers

Persistent elevated C-reactive protein after treatment is an independent marker of a poor prognosis in patients with hepatocellular carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer